IMDX · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
This Form 12b-25 (Notification of Late Filing) is being filed by Oncocyte Corporation (the “ Company ”) to seek an extension of the filing deadline for its Annual Report on Form 10-K for the year ended December 31, 2023 (the “ Annual Report ”) pursuant to Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended. The due date for the filing of the Annual Report is April 1, 2024. The Company is unable to file the Annual Report by the prescribed filing deadline without unreasonable effort and expense, because it requires additional time to complete the preparation of its financial statements and other disclosures in the Annual Report, including those related to certain subsequent events. The Company currently expects to file the Annual Report within the 15-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended
NT 10-K, filed 2024-04-01 · accounts not ready
2025-04-17auditor changed or resigned SEC →
This Form 12b-25 (Notification of Late Filing) is being filed by Oncocyte Corporation (the “ Company ”) to seek an extension of the filing deadline for its Annual Report on Form 10-K for the year ended December 31, 2023 (the “ Annual Report ”) pursuant to Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended. The due date for the filing of the Annual Report is April 1, 2024. The Company is unable to file the Annual Report by the prescribed filing deadline without unreasonable effort and expense, because it requires additional time to complete the preparation of its financial statements and other disclosures in the Annual Report, including those related to certain subsequent events. The Company currently expects to file the Annual Report within the 15-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended
2023-10-05auditor changed or resigned SEC →
Oncocyte Corporation (the “Registrant”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”). The compilation, dissemination and review of the information required to be presented in the Form 10-K for the relevant period, including, without limitation, the financial statements to be included therein, has imposed time constraints that have rendered timely filing of the Form 10-K impracticable without undue hardship and expense to the Registrant. The Registrant undertakes the responsibility to file, and anticipates that it will file, the Form 10-K no later than fifteen days after its original prescribed due date
2021-07-20auditor changed or resigned SEC →
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice